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Abstract
One of the key requirements for incorporating
machine learning into the drug discovery pro-
cess is complete reproducibility and traceabil-
ity of the model building and evaluation pro-
cess. With this in mind, we have developed
an end-to-end modular and extensible software
pipeline for building and sharing machine learn-
ing models that predict key pharma-relevant
parameters. The ATOM Modeling PipeLine,
or AMPL, extends the functionality of the open
source library DeepChem and supports an array
of machine learning and molecular featurization
tools. We have benchmarked AMPL on a large
collection of pharmaceutical datasets covering
a wide range of parameters. Our key findings
include:
• Physicochemical descriptors and deep
learning-based graph representations sig-
nificantly outperform traditional finger-
prints in the characterization of molecular
features.
• Dataset size is directly correlated to pre-
diction performance, and that single-task
deep learning models only outperform
shallow learners if there is sufficient data.
Likewise, dataset size has a direct im-
pact on model predictivity, independent
of comprehensive hyperparameter model
tuning. Our findings point to the need
for public dataset integration or multi-
task/transfer learning approaches.
• Uncertainty quantification (UQ) analysis
may help identify model error; however,
efficacy of UQ to filter predictions varies
considerably between datasets and featur-
ization/model types.
AMPL is open source and available for down-
load at http://github.com/ATOMconsortium/
AMPL.
Introduction
Discovery of new compounds to treat human
disease is a multifaceted process involving the
selection of chemicals with favorable pharmaco-
logical properties: a high potency to the desired
target, elimination or minimization of safety li-
abilities, and a favorable pharmacokinetic (PK)
profile. To address this challenge, the drug
discoverer has a wealth of choices, with to-
tal “drug-like” chemical matter estimated be-
tween 1022-1060 unique molecules. However,
evaluating the desirability of these molecules
with respect to potency, pharmacokinetics, and
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safety liabilities is a time-consuming and ex-
pensive process. Many of these molecules re-
quire de novo synthesis, which is a rate-limiting
step. Furthermore, evaluation of pharmacolog-
ical properties both in vitro and especially in
vivo is prohibitively expensive given the uni-
verse of possible choices.
To aid in this design challenge, the field
of computer-aided drug design has evolved to
rapidly predict the properties of pharmacologi-
cal matter in silico, allowing for rational selec-
tion of a feasible set compounds for synthesis
and evaluation. These techniques generally fall
into two categories: (1) structure-based drug
design, which relies on knowledge of the tar-
get structure (i.e. docking, molecular dynam-
ics, free energy perturbation) and (2) ligand-
based drug design, which uses known properties
of molecules to develop models of quantitative
structure-activity relationships (QSAR).
Ligand-based drug design generally relies on
machine learning-based techniques to identify
the link between structure and the property
of interest. Recently, a proliferation of ad-
vanced machine learning techniques have shown
great promise in increasing the predictability of
QSAR models. A deep learning model first won
the Merck Kaggle multi-activity challenge in
2014,1 and since then these models have contin-
ued to show increased predictive accuracy over
QSAR models based on classical machine learn-
ing techniques in many studies.2 A recent ex-
ample of success with deep learning is the paper
by Feinberg et al. that compared the Potential-
Net deep learning method with existing shallow
learners on a wide array of pharmaceutically-
relevant datasets.3 These results showed dra-
matic improvements for deep learning based
on temporal splits using data collected from a
pharmaceutical company. Another evaluation
showed that a directed message-passing neu-
ral network model can provide robust perfor-
mance over a range of experimental datasets
characterizing molecular properties.4 The au-
thors provide an open-source deep learning soft-
ware to go with this paper that has been tested
on a wide range of parameters. However, this
software does not include any type of modu-
lar pipeline that would allow for the incorpo-
ration of different models and chemical repre-
sentations. Overall there has been a lack of
publicly available suites of software tools that
support a transparent and reproducible genera-
tion of a diverse array of deep and classical ma-
chine learning models, especially ones that can
scale to model the large set of pharmaceutically-
relevant parameters. A major advance towards
this goal was made with the introduction of
DeepChem,5 which supports the building of a
variety of machine learning models for small
molecule property prediction. DeepChem con-
tains a variety of very helpful modules and
tools, but has limitations in its ability to ro-
bustly train models from a wide selection of
hyperparameters, and published performance
evaluation is limited to a small number of public
datasets with less diverse pharmaceutical rele-
vance.6
In this paper we introduce a new small
molecule property prediction pipeline, AMPL.
This software was developed through the Accel-
erating Therapeutics Opportunities in Medicine
(ATOM) Consortium as the ATOM Model-
ing PipeLine. The key contributions of this
work are to automate deep learning train-
ing, particularly in hyperparameter search; to
enable extensive performance benchmarking;
and to apply AMPL to a large collection of
pharmaceutically-relevant property-prediction
datasets. Most notably, AMPL is available as
open source to benefit the drug discovery com-
munity.
The closest existing pipeline tools are
BIOVIA Pipeline Pilot7 and KNIME.8 Pipeline
Pilot is a license-based graphical tool for ma-
chine learning pipelining. It has capabilities for
data cleaning, splitting, training, and model
deployment, but are all mainly GUI-based,
limiting the customizability of the software.
Furthermore, it is only available for a licens-
ing fee, so it does not target the open source
community. In terms of free and open source
software suites for data analytics, the main al-
ternative is KNIME. This software provides an
environment for creating general data flows to
process data, use predictive models, and ana-
lyze complex datasets. An ecosystem of open
source and commercial KNIME node exten-
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sions has developed which enable workflows
for library analyses, virtual screening, model
fitting and prediction. In contrast, AMPL is
tightly focused on integrating modern machine
learning methods with best practices for chem-
ical activity and property prediction. Impor-
tant issues with machine learning models, such
as dataset characterization, model validation,
and uncertainty quantification are addressed by
AMPL in automated and reproducible ways.
The code suite also provides high performance
computing modules for model fitting, hyperpa-
rameter optimization, and predictions. AMPL
currently targets job submission-based clus-
ters to scale training runs; however, AMPL
could be adapted to operate on other scalable
platforms such as Spark in the future. Fur-
thermore, AMPL is implemented as a modular
and reusable Python library to allow for easy
integration with other data science software
platforms.
An extensive set of experiments were con-
ducted with AMPL, and key observations in-
clude:
• Physicochemical descriptors and deep
learning-based graph representations are
significantly better than traditional fin-
gerprints to characterize molecular fea-
tures
• Dataset size is directly correlated to per-
formance of prediction: single-task deep
learming models only outperform shallow
learners if there is enough data. Like-
wise, data set size has a direct impact of
model predictivity independently of com-
prehensive hyperparameter model tuning.
Our findings point to the need for public
dataset integration or multi- task/ trans-
fer learning approaches.
• DeepChem uncertainty quantification
(UQ) analysis may help identify model
error; however, efficacy of UQ to filter
predictions varies considerably between
datasets and model types.
The aim of this paper is to present the rig-
orous and transparent open source software
pipeline AMPL to build global and local ‘base-
line’ models for a wide array of molecular prop-
erties that are needed for in silico drug dis-
covery. This new software will support repro-
ducible training and testing protocols that en-
able the broader modeling community to eval-
uate and improve modeling approaches over
time.
Methods
Figure 1 shows the overall architecture of
AMPL. This end-to-end pipeline supports all
functions needed to generate, evaluate, and save
machine learning models: data ingestion and
curation, featurization of chemical structures
into feature vectors, training and tuning of
models, storage of serialized models and meta-
data, and visualization and analysis of results.
It also contains modules for parallelized hyper-
parameter search on high-performance comput-
ing (HPC) clusters.
Data curation
AMPL includes several modules to curate data
into machine learning-ready datasets. Func-
tions are provided to represent small molecules
with canonicalized SMILES strings using RD-
Kit9 and the MolVS package,10 by default strip-
ping salts and preserving isomeric forms. Data
curation procedures are provided with AMPL
as Jupyter notebooks,11 which can be used as
examples for curating new datasets. Procedures
allow for averaging response values for com-
pounds with replicate measurements and filter-
ing compounds with high variability in their
measured response values. AMPL also provides
functions to assess the structural diversity of
the dataset, using either Tanimoto distances
between fingerprints, or Euclidean distances be-
tween descriptor feature vectors.
Data ingestion and curation-related parame-
ters include:
• Unique human readable name for training
file
• Data privilege access group
3
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Figure 1: Overview of AMPL
• Parameter for overriding the output
files/dataset object names
• ID for the metadata + dataset
• Boolean flag for using an input file from
the file system
• Name of column containing compound
IDs
• Name of column containing SMILES
strings
• List of prediction task names
• Number of classes for classification
• User specified list of names of each class
• Boolean switch for using transformation
on regression output. Default is True
• Response column normalization type
• Minimum number of dataset compounds
considered adequate for model training.
A warning message will be issued if the
dataset size is less than this.
Featurization
AMPL provides an extensible featurization
module which can generate a variety of molec-
ular feature types, given SMILES strings as in-
put. They include:
• Extended connectivity fingerprints
(ECFP) with arbitrary radius and bit
vector length12
• Graph convolution latent vectors, as im-
plemented in DeepChem13
• Chemical descriptors generated by the
Mordred open source package14
• Descriptors generated by the commer-
cial software package Molecular Operat-
ing Environment (MOE)15
• User-defined custom feature classes
Because some types of features are expensive
to compute, AMPL supports two kinds of in-
teraction with external featurizers: a dynamic
mode in which features are computed on-the-
fly and a persistent mode whereby features are
read from precomputed tables and matched by
compound ID or SMILES string. In the persis-
tent mode, when SMILES strings are available
as inputs, the featurization module matches
them against the precomputed features where
possible, and computes features dynamically for
the remainder. Because precomputed feature
tables may span hundreds or thousands of fea-
ture columns for millions of compounds, the
module uses the feather format16 to speed up
access.
Featurized datasets for feature types that
support persistent mode (currently, all except
ECFP fingerprints and graph convolution for-
mat) are saved in the filesystem or remote data-
store, so that multiple models can be trained
on the same dataset. This also facilitates re-
producibility of model results.
Chemical descriptor sets such as those gener-
ated by MOE often contain descriptors that are
exact duplicates or simple functions of other de-
scriptors. In addition, large blocks of descrip-
tors may be strongly correlated with one an-
other, often because they scale with the size of
the molecule. The featurization module deals
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with this redundancy by providing an option
to remove duplicate descriptors and to scale a
subset of descriptors by the number of atoms in
the molecule (while preserving the atom count
as a distinct feature). Factoring out the size
dependency often leads to better predictivity
of models.
The featurization module can be easily ex-
tended to handle descriptors generated by other
software packages, latent vectors generated by
autoencoders, and other types of chemical fin-
gerprints. In most cases, this can be accom-
plished by writing a small function to invoke
the external feature generation software, and
by adding an entry to a table of descriptor
types, listing the generated feature columns to
be used. In more complicated cases, one may
need to write a custom subclass of one of the
base featurization classes.
Featurization-relevant input parameters in-
clude:
• Type of molecule featurizer
• Feature matrix normalization type
• Boolean flag for loading in previously fea-
turized data files
• Type of transformation for the features
• Radius used for ECFP generation
• Size of ECFP bit vectors
• Type of autoencoder, e.g. molvae, jt
• Trained model HDF5 file path, only
needed for MolVAE featurizer
• Type of descriptors, e.g. MOE, Mordred
• Max number of CPUs to use for Mordred
descriptor computations. None means use
all available
• Base of key for descriptor table file
Dataset partitioning
AMPL supports several options for partition-
ing datasets for model training and evaluation,
By default, datasets are split into 3 parts: a
training set, a validation set (for parameter
selection), and a holdout test set (for evalu-
ation). Alternatively, AMPL offers a k-fold
cross-validation option, to assess the perfor-
mance impact of sampling from the modeled
dataset. Under k-fold cross-validation, the
holdout test set is selected first, and the remain-
der is divided into k-fold sets for training and
validation.
AMPL offers a number of dataset splitting al-
gorithms, which offer different approaches to
the problem of building models that general-
ize from training data to novel chemical space.
It supports several of the methods included
in DeepChem, including random splits, Butina
clustering, Bemis-Murcko scaffold splitting, and
a simple algorithm based on fingerprint dis-
similarity.6 In addition, we implemented tem-
poral splitting and a modified version of the
asymmetric validation embedding (AVE) debi-
asing algorithm.17 We compared random split-
ting with Bemis-Murcko scaffold splitting for
our benchmarking experiments.
Input parameters related to data splitting in-
clude:
• Type of splitter to use: index, random,
scaffold, Butina, ave min, temporal, fin-
gerprint, or stratified
• Boolean flag for loading in previously-
split train, validation, and test CSV files
• UUID for CSV file containing train, vali-
dation, and test split information
• Choice of splitting type between k-
fold cross validation and a normal
train/valid/test split
• Number of k-folds to use in k-fold cross
validation
• Type of splitter to use for train/validation
split if temporal split used for test set
(random, scaffold, or ave min)
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• Cutoff Tanimoto similarity for clustering
in Butina splitter
• Cutoff date for test set compounds in
temporal splitter
• Column in dataset containing dates for
temporal splitter
• Fraction of data to put in validation set
for train/valid/test split strategy
• Fraction of data to put in held-out test
set for train/valid/test split strategy
Model training and tuning
AMPL includes a train/tune/predict frame-
work to create high-quality models. This frame-
work supports a variety of model types from two
main libraries: scikit-learn18 and DeepChem.5
Currently, specific input parameters are sup-
ported for:
• Random forest models from scikit-learn
• XGBoost models19
• Fully connected neural network models
• Graph convolution neural network mod-
els20
As with the featurization module, AMPL sup-
ports integration of custom model sub-classes.
Parameters for additional models can be easily
added to the parameter parser module.
Model-relevant input parameters include:
• Type of model to fit (neural network, ran-
dom forest, or xgboost)
• Prediction type (regression or classifica-
tion)
• Singletask or multitask model
• Number of decision trees in the forest for
random forest models
• Max number of features to split random
forest nodes
• Number of estimators to use in random
forest models
• Batch size for neural network model
• Optimizer type for neural network model
• Optimizer specific for graph convolutional
models, defaults to “adam”
• Model batch size for neural network
model
• List of hidden layer sizes for neural net-
work model
• List of dropout rates per layer neural net-
work model
• List of standard deviations per layer for
initializing weights for neural network
model
• The type of penalty to use for weight de-
cay, either “l1” or “l2”
• The magnitude of the weight decay
penalty to use
• List of initial bias parameters per layer for
neural network model
• Learning rate for dense neural network
models
• Epoch for evaluating baseline neural net-
work model performance, if desired
• Maximum number of training epochs for
neural network model
• Type of score function used to choose best
epoch and/or hyperparameters
• Boolean flag for computing uncertainty
estimates for regression model predictions
Epoch selection for neural network mod-
els
Early stopping is an essential strategy to avoid
overfitting of neural networks, thus the number
of training epochs is one of the key hyperparam-
eters that must be optimized. To implement
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early stopping, AMPL trains neural network
models for a user-specified maximum number of
epochs, evaluating the model on the validation
set after each epoch, and identifies the epoch at
which a specified performance metric is maxi-
mized. By default this metric is the coefficient
of determination R2 for regression models, and
the area under the receiver operating character-
istic curve (ROC AUC) for classification mod-
els.
Model persistence
Serialized models are saved after training and
prediction generation are complete, along with
detailed metadata to describe the model. This
supports traceability and reproducibility, as
well as model sharing. AMPL supports saving
models and results either using the file system
or optionally through a collection of database
services. The metadata can be stored in a mon-
goDB database21 or as JSON files. AMPL has
functions for saving models and loading pre-
built models for prediction generation.
Model performance metrics
AMPL calculates a variety of performance met-
rics for predictions on the training, validation
and test sets. Metrics may be saved in a mon-
goDB database or in JSON files. For regression
models, we calculate:
• Coefficient of determination (R2). This
is calculated using sklearn’s metrics func-
tion. Note that this score can be negative
if the model is arbitrarily worse than ran-
dom.
R2(y, yˆ) = 1−
∑n
i=1(yi − yˆi)2∑n
i=1(yi − y¯)2
(1)
• Mean Absolute Error (MAE). An advan-
tage of MAE is that it has a clear inter-
pretation, the average absolute difference
between the measured value yi and pre-
dicted value yˆi. This works well for cellu-
lar activity assay datasets, which use log
normalized dose concentration value with
similar concentration ranges across differ-
ent assays. PK parameters are measured
on different scales for some assays, which
prevents comparison between assays with
this metric.
MAE =
∑n
i=1 |yi − yˆi|
n
(2)
• Mean Square Error (MSE). This is a
risk metric corresponding to the expected
value of the squared error (or loss).
MSE(y, yˆ) =
1
n
n−1∑
i=0
(yi − yˆi)2 (3)
For classification models, we calculate:
• Area Under the Receiver Operating Char-
acteristics Curve (ROC AUC). The ROC
curve plots the True Positive Rate versus
the False Positive Rate as a binary clas-
sifier’s discrimination threshold is varied.
The ROC AUC score is calculated by find-
ing the area under the ROC Curve. This
value can range from 0 – 1, where 1 is the
best score.
• Precision (Positive Predictive Value)
Precision =
TP
TP + FP
(4)
where TP = number of true positives and
FP = number of false positives
• Recall (True positive rate/ sensitivity)
Recall =
TP
TP + TN
(5)
where TP = number of true positives and
TN = number of true negatives
• Area under the precision-recall curve
(PRC-AUC). The precision-recall curve
plots precision versus recall as a binary
classifier’s discrimination threshold is var-
ied. It is a good measure of success of pre-
diction when classes are very imbalanced.
High scores show that the classifier is re-
turning accurate results (high precision),
7
as well as returning a majority of all pos-
itive results (high recall).
• Negative Predictive Value (NPV)
NPV =
TN
TN + FN
(6)
where TN = number of true negatives and
FN = number of false negatives
• Cross entropy (log loss)
Cross entropy = −
M∑
c=1
yo,clog(po,c) (7)
• Accuracy
Accuracy =
TP + TN
TP + TN + FP + FN
(8)
where terms are defined as above.
Uncertainty quantification
Uncertainty quantification (UQ) attempts to
measure confidence in a model’s prediction ac-
curacy by characterizing variance in model pre-
dictions. Some common objectives for UQ are
to use it to guide active learning or to weight
model ensembles. AMPL generates UQ val-
ues for both random forest and neural network
models.
Uncertainty quantification for random
forest
Generating a value quantifying uncertainty is
straightforward for random forest and is taken
to be the standard deviation of predictions from
individual trees. This quantifies how variable
these predictions are, and thus how uncertain
the model is in its prediction for a given sample.
Uncertainty quantification for neural net-
works
Our neural network-based UQ uses the
Kendall and Gal method22 as implemented
in DeepChem. This method combines aleatoric
and epistemic uncertainty values.
Aleatoric uncertainty cannot be reduced by
adding more data but can be estimated. It is
estimated by modifying the loss function of the
model to predict both the response variable and
the error of the model.
Epistemic uncertainty arises because of lim-
ited data. It represents the uncertainty of the
model. Normally this is calculated in a boot-
strapped manner, as in the case of a random
forest. However, since training neural networks
is expensive, an alternate approach is to train
one network to generate a set of predictions by
applying a set of dropout masks during predic-
tion. Prediction variability is then quantified to
assess epistemic uncertainty.
Visualization and analysis
Plots generated by AMPL’s visualization and
analysis module are shown in the Results sec-
tion. Additional options include plots of pre-
dicted vs. actual values, learning curves, ROC
curves, precision vs. recall curves, and 2-D pro-
jections of feature vectors using UMAP.23 The
module also includes functions for characteriz-
ing and visualizing chemical diversity. Chemi-
cal diversity analysis is crucial for analyzing do-
main of applicability, bias in dataset splitting,
and novelty of de novo compounds. This mod-
ule supports a wide range of input feature types,
distance metrics, and clustering methods.
Hyperparameter optimization
A module is available to support distributed
hyperparameter search for HPC clusters. This
module currently supports linear grid, logistic
grid, and random hyperparameter searches, as
well as iteration over user-specified values. To
run the hyperparameter search, the user spec-
ifies the desired range of configurations in a
JSON file. The user can either specify a single
dataset file or a CSV file with a list of datasets.
The script generates all valid combinations of
the specified hyperparameters, accounting for
model and featurization type, and submits jobs
for each combination to the HPC job sched-
uler. The module includes an option to gen-
erate a pre-featurized and pre-split dataset be-
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fore launching the model training runs, so that
all runs operate on the same dataset split. The
user can specify a list of layer sizes and dropouts
to combine, along with the maximum final layer
size and a list of the numbers of possible lay-
ers for a given model, and the module com-
bines these different options based on the in-
put constraints to generate a variety of model
architectures. The search module can check
the model tracker database to avoid retraining
models that are already available. It also pro-
vides users the option to exclude hyperparam-
eter combinations that lead to overparameter-
ized models, by checking the number of weight
and bias parameters for a proposed neural net-
work architecture against the size of the train-
ing dataset. Finally, the search module throt-
tles job submissions to prevent the user from
monopolizing the HPC cluster.
Input parameters for hyperparameter search
include:
• Boolean flag indicating whether we are
running the hyperparameter search script
• UUID of hyperparam search run model
was generated in
• Comma-separated list of number of layers
for permutation of NN layers
• Comma-separated list of dropout rates for
permutation of neural network layers
• The maximum number of nodes in the last
layer
• Comma-separated list of number of nodes
per layer for permutation of neural net-
work layers
• Maximum number of jobs to be in the
queue at one time for an HPC cluster
• Scaling factor for constraining network
size based on number of parameters in the
network
• Boolean flag directing whether to check
model tracker to see if a model with that
particular param combination has already
been built
• Path where pipeline file you want to run
hyperparam search from is located
• Type of hyperparameter search to do.
Options are grid, random, geometric, and
user specified
• CSV file containing list of datasets of in-
terest
Running AMPL
There are three ways to run AMPL:
• Using a config file: Create a JSON file
with desired model parameters and run
full pipeline via command line
• Using command line arguments: Specify
model parameters via standard command
line arguments
• Interactively in a Jupyter notebook using
an argparse.Namespace object or a dictio-
nary
Results
Benchmark experiments were run to evaluate
and validate components of the pipeline.
Data
Experimental datasets were made available by
ATOM Consortium member GlaxoSmithKline
from a variety of bioactivity and pharmacoki-
netics experiments. Selected datasets were used
for training and evaluating models. These
datasets are summarized in Table 1.
Pharmacokinetic (PK) and safety datasets
were curated separately, as they contain dif-
ferent types of experimental data and thus re-
quire different processing. The raw datasets
were cleaned to remove rows with outlying,
missing, and duplicate measurements, and pro-
cessed to yield machine learning datasets with
a single aggregate value per unique compound.
These procedures informed the design of cura-
tion functions included in the pipeline. Cura-
tion of the PK datasets required the conversion
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of values to standard units, the removal of com-
pounds with stability or recovery issues, and
the exclusion of data that was generated using
significantly different assay protocols. Subse-
quently, replicate experimental measurements
were identified by matching duplicate canoni-
cal SMILES strings and averaged to produce a
single value per compound.
For the safety datasets, censored measure-
ments were an additional concern. Since bioac-
tivity assays are typically performed over a lim-
ited range of compound concentrations, IC50 or
EC50 values may be reported as being above or
below a maximum or minimum concentration,
so that the measurements are censored. When
all measurements for a compound are censored
in the same direction, the user is given the op-
tion to either exclude the compound from the
dataset, or include it with a relational operator
indicating the direction together with the cen-
soring threshold. In the case where some repli-
cate measurements are censored and some are
not, AMPL computes a maximum likelihood es-
timate for the mean activity, assuming a Gaus-
sian distribution of measurements around the
true mean. The distribution of response values
is reported along with the mean and standard
deviation.
Experimental design for regression
pharmacokinetic models
To evaluate AMPL’s performance, we built a
total of 11,552 models on 15 pharmacokinetic
datasets and 26 bioactivity datasets. These
models include 9,422 regression models and
2,130 classification models.
We evaluated a variety of deep learning model
types and architectures and compared them
to baseline random forest models. We ex-
plored the performance of four types of features:
ECFP fingerprints, MOE descriptors, Mordred
descriptors, and graph convolution-based latent
vectors. For the neural network models, we
searched over many combinations of learning
rates, numbers of layers, and nodes per layer.
For each combination of neural network hyper-
parameters, we trained for up to 500 epochs
and used a validation set performance metric
(R2 for regression, ROCAUC for classification)
to choose an early stopping epoch for the fi-
nal model. For random forest models, the only
hyperparameter varied was the maximum tree
depth, as previous experiments showed that
other model hyperparameters had a minimal ef-
fect for our datasets. The complete set of hy-
perparameters varied was as follows:
• Splitter Types: scaffold and random
• Fraction for train set: 0.7
• Fraction for validation set: 0.1
• Fraction for holdout set: 0.2
• Feature types: ECFP, MOE, mordred,
and graph convolution
• Model types: neural network and random
forest
• Neural network learning rates: 0.0001,
0.00032, 0.001, 0.0032, 0.01
• Maximum number of epochs: 500
• Number of layers: 1,2
• Layer size options: 1024,256,128, 64,
32,16,8,4,1
• Maximum final layer size: 16
• Dropout rate: 0.1
Analysis of modeling performance
To identify which featurization type generated
the most predictive models for each model type,
models with the best validation set R2 score
were selected for each model/splitter/dataset
combination. The number of “best” models for
which each feature type yielded the highest test
set R2 score is plotted in Figure 2. Figure 2
shows that the chemical descriptors generated
by the commercial MOE software outperformed
those produced by the open source Mordred
package in most cases. DeepChem’s graph con-
volution networks outperform all other feature
types for neural network models.
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Table 1: Pharmacokinetics datasets used to benchmark AMPL
Dataset Units Species Dataset Size Minimum Maximum Mean Median
Blood to Plasma Ratio Human 101 0.47 10.5 0.85 0.77
Blood to Plasma Ratio Dog 71 0.37 6.85 0.85 0.88
Plasma Protein Binding HSA fraction unbound Human 123734 0.0001 1 0.05 0.044
Plasma Protein Binding HSA fraction unbound Rat 2086 0.0001 1 0.036 0.033
Plasma Clearance (In Vivo) mL/min/kg Dog 1181 0.1 2946 12.6 15.2
Plasma Clearance (In Vivo) mL/min/kg Rat 10431 0.001 8763 30.2 38.2
Vd,ss L/kg Dog 1054 0.07 569 1.9 1.9
Vd,ss L/kg Rat 9681 0.01 2080 2.3 2.4
Hepatocyte Clearance mL/min/g liver tissue Human 1695 0.01 97 1.6 1.5
Hepatocyte Clearance mL/min/g liver tissue Dog 630 0.1 504 2 1.8
Hepatocyte Clearance mL/min/g liver tissue Rat 2098 0.02 878 2.9 2.9
Microsomal Clearance mL/min/g liver tissue Human 29162 0 156 2.8 2.4
Microsomal Clearance mL/min/g liver tissue Dog 2080 0.03 150 2.5 1.8
Microsomal Clearance mL/min/g liver tissue Rat 30563 0.01 198 3.9 3.7
LogD 27345 0.01 53703 258 407
Table 2: Safety datasets used to benchmark AMPL
Assay Target Primary Liability Experimental System Detection
BSEP pIC50 Bile Salt Export Pump Hepatic membrane vesicles
ADRA1B pIC50 Adrenergic α1B pIC50 CNS Intracell Ca
ADRA2C pIC50 α2C Adrenoceptor CNS CHO K1
ADRB2 pEC50 β2 Adrenoceptor CNS FRET
CHRM1 pEC50 Cholinergic Receptor Muscarinic 1 CNS CHO Intracellular Ca Fluorescence
CHRM1 pIC50 Cholinergic Receptor Muscarinic 1 CNS CHO Intracellular Ca Fluorescence
CHRM2 pEC50 Cholinergic Receptor Muscarinic 2 CNS CHO Intracellular Ca Fluorescence
DRD2 pEC50 Dopamine D2 CNS HEK293F Low Na GTPgS SPA
GRIN1 pIC50 GRIN1 GRIN2B NR2B NR1A 2B Subunit pIC50 CNS
HRH1 pIC50 Histamine Receptor H1 CNS Luminescence
HTR1B pIC50 5-hydroxytryptamine receptor 1B CNS 10ul LEADseeker GTPgS
HTR2A pEC50 5-hydroxytryptamine Receptor 2A CNS HEK Luminescence
HTR2A pIC50 5-hydroxytryptamine Receptor 2A CNS HEK Luminescence
HTR2C pEC50 5-hydroxytryptamine Receptor 2C CNS CHO Luminescence
HTR2C) pIC50 5-hydroxytryptamine Receptor 2C CNS CHO Luminescence
HTR3A pIC50 5-hydroxytryptamine Receptor 3A CNS FLIPR
KCNA5 (Kv1.5) pIC50 KCNA5 (Kv1.5) Cardiovascular CHO Electrophys
KCNE1 KCNQ1 (Kv7.1) pIC50 KCNE1 KCNQ1 (Kv7.1) Cardiovascular MinK Human Blocker CHO Electrophys
MAOA pIC50 Monoamine Oxidase A CNS FLINT
PDE3A pIC50 Phosphodiesterase 3A Cardiac SPA(cAMP Inhibition)
PDE4B pIC50 Phosphodiesterase 4B CNS SPA
Phospholipidosid pEC50 Phospholipidosis Induction Cellular Tox HEPG2 FLINT
PI3Kγ pIC50 Phosphoinositide 3-kinase γ (pI3Kγ) Cellular Tox TR FRET
COX 2 pIC50 Cyclooxygenase 2 Cardiovascular FLINT SAR
SCN5A (NaV1.5) pIC50 SCN5A (NaV1.5) Cardiovascular
SCL6A2 pIC50 Noradrenaline Transporter NET CNS BacMam Bind SPA
SLC6A4 pIC50 Seratonin Transporter (SERT) CNS BacMam binding SPA
OATP1B1 pIC50 Organic Anion Transport Polypeptide (SLCO1B1) Hepatic HEK Image
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Figure 2: Number of times each featurization
type produces the best model for the 15 PK
datasets
The model/featurization combination with
the most accurate predictions on the holdout
set is shown in Figure 3. MOE featurization
with random forest models most frequently out-
performed other featurization/model type com-
binations for both types of splitters.
Figure 4 confirms that random forest models
tend to outperform neural network models for
the evaluated datasets.
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Figure 3: Number of times each featurization
type/ model type combination produces the
best model for the 15 PK datasets
Random Split Scaffold Split
0
2
4
6
8
Fr
eq
ue
nc
y 
of
 B
es
t T
es
t S
et
 R
2
Neural network
Random Forest
Figure 4: Number of times each model type
produces the best model for the 15 PK datasets
Investigation into neural network
performance
Neural networks are known to perform more
poorly on smaller datasets, so we wanted to
examine the relationship between the size of
a dataset and the test set R2 values for the
best random forest and neural network mod-
els for that dataset. Figure 5 shows the test
set R2 values for the best neural network and
random forest models for each dataset, where
best is defined as the model with the highest
validation set R2 value. The figure shows that
as the dataset size increases, the R2 score for
the test set increases as well. The pattern is
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Figure 5: Plot of best test set R2 values versus
the dataset size for neural network and random
forest models
true for the overall best model, regardless of
type, for both regression and classification, as
shown in Figure 6. These results indicate that
we will need to augment our datasets to further
improve model performance. We plan to ex-
plore multiple avenues to address this require-
ment: conducting additional experiments, run-
ning simulations, sourcing public data, build-
ing multi-task models, and experimenting with
transfer learning approaches.
Figure 6: Per-dataset model accuracy versus
dataset size
We also examined the architectures that
yielded the best model for each feature type for
the neural network models. Our hypothesis was
that larger datasets would perform better with
larger networks. Figure 7 shows number of pa-
rameters in the hidden layers of the model ver-
sus the size of the dataset. The color indicates
the dataset and the shape indicates the featur-
izer type. The number of parameters for the
2-layer networks was calculated by multiplying
the first and second layers together. We can see
a clear lower bound in the number of parame-
ters for the best network for all featurizer types
as the dataset size increases.
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Figure 7: Number of hidden layer parameters
versus number of samples for the best model for
each dataset/featurizer combination
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Summary of model performance
Figure 8 and Figure 9 show the full set of test
set R2 values for the best model for each molec-
ular featurization representation and model
type for random and scaffold splits respectively
(picked as before by the best validation set R2
value). Random sampling inflates the R2 values
of the holdout set, which is as expected since
there is greater structural overlap between the
set of compounds in the training and holdout
set. For scaffold split-generated holdout sets,
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Figure 8: Performance accuracy for regression
for random split
there is a very clear pattern between dataset
size and R2 value, although the complexity
of the predicted property and quality of the
dataset also obviously has an effect.
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Figure 9: Performance accuracy for regression
for scaffold split
Model tuning results
To evaluate whether hyperparameter search im-
proves model performance, the test set R2
for a baseline model was compared with the
test set R2 from the best-performing model
selected by looking at the validation set R2
value. Small datasets and ECFP-based mod-
els, which showed poor neural network perfor-
mance overall, showed little to no improvement,
while better-performing datasets and featuriz-
ers showed greater improvement with hyperpa-
rameter search. This suggests that data aug-
mentation will be necessary to improve predic-
tion performance on the smaller problematic
datasets, and that ECFP is a poor featurizer
no matter the hyperparameters.
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Figure 10: Histogram of improvement in R2 val-
ues for the test set for the four featurizers for
neural network models
Classification experiments
A set of classification model experiments were
also conducted for a panel of 28 bioactivity
datasets, without any hyperparameter tuning.
In total 2,130 neural network and random for-
est models were generated. A dose concentra-
tion threshold was used to label active and in-
active compounds on a per-dataset basis us-
ing thresholds provided by domain experts at
GlaxoSmithKline. The classes were extremely
unbalanced, which partially explains the high
ROC-AUC scores.
Uncertainty quantification
To explore the utility of the uncertainty quan-
tification values produced by neural network
and random forest models, a case study is pre-
sented for three representative PK parameter
datasets: rat plasma clearance (in vivo), hu-
man microsomal clearance, and human plasma
protein binding HSA. These datasets were se-
lected to represent small, medium, and large
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Figure 11: Performance accuracy for classifica-
tion
sized datasets with low, medium, and high R2
values.
Precision-recall plot analysis
Precision-recall curves measure the fraction of
low error predictions made at varying UQ
thresholds. Precision is defined as the frac-
tion of predictions with UQ values less than the
UQ threshold, with error less than some prede-
fined threshold. For this analysis we use mean
logged error and define “low-error” as samples
with logged error below the mean (log served to
normalize the distribution). Recall reports the
fraction of low-error samples which pass the UQ
filter threshold. Overall, we would like to use
the UQ value as a threshold to identify low er-
ror samples at a higher rate than in the overall
test set. Table 3 shows the percentage of low
error samples in the test set as a whole for each
dataset/model/featurizer combination.
In general, a low UQ threshold with accu-
rate uncertainty would correspond to a preci-
sion of 1, which means confident predictions
correspond to low-error predictions. To have
the greatest utility, the curve should keep fairly
high precision as the recall increases. UQ suc-
cessfully filters out low confidence predictions in
some cases but performance varies widely with
Table 3: Percent of total low-error sam-
ples in the test set for the specified dataset,
model/featurizer combinations
Dataset Model and featurizer type
Percent of total
low error samples
Rat Plasma Clearance (In Vivo) Neural network + ECFP 41.4%
Rat Plasma Clearance (In Vivo) Neural network + GraphConv 41.8%
Rat Plasma Clearance (In Vivo) Neural network + MOE 42.9%
Rat Plasma Clearance (In Vivo) Neural network + Mordred 40.5%
Rat Plasma Clearance (In Vivo) Random forest + ECFP 42.5%
Rat Plasma Clearance (In Vivo) Random forest + MOE 41.7%
Rat Plasma Clearance (In Vivo) Random forest + Mordred 42.0%
Human Microsomal Clearance Neural network + ECFP 41.0%
Human Microsomal Clearance Neural network + GraphConv 41.0%
Human Microsomal Clearance Neural network + MOE 39.0%
Human Microsomal Clearance Neural network + Mordred 39.8%
Human Microsomal Clearance Random forest + ECFP 39.5%
Human Microsomal Clearance Random forest + MOE 38.5%
Human Microsomal Clearance Random forest + Mordred 39.6%
Human Plasma Protein Binding HSA Neural network + ECFP 43.4%
Human Plasma Protein Binding HSA Neural network + GraphConv 43.0%
Human Plasma Protein Binding HSA Neural network + MOE 43.1%
Human Plasma Protein Binding HSA Neural network + Mordred 43.5%
Human Plasma Protein Binding HSA Random forest + ECFP 42.0%
Human Plasma Protein Binding HSA Random forest + MOE 42.8%
Human Plasma Protein Binding HSA Random forest + Mordred 42.5%
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Figure 12: Precision-recall plot for rat plasma
clearance (in vivo), varying UQ value
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Figure 13: Precision-recall plot for human mi-
crosomal clearance, varying UQ value
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Figure 14: Precision-recall plot for human
plasma protein binding HSA, varying UQ value
the model/featurization type and the dataset.
Figures 12, 13 and 14 show that precision drops
quickly as recall increases and for some models
precision is poor even when applying the lowest
UQ threshold. Nevertheless, for each dataset
there exists a UQ threshold for at least one
model which could be used to increase the frac-
tion of low error predictions over the baseline
percentages shown in Table 3. For example,
Figure 14 suggests that applying a UQ thresh-
old could increase precision to 65% from around
42% with a recall of 10%. Later it is shown
that for the human plasma protein binding HSA
dataset, this could still yield a collection of com-
pounds with a diverse range of response values.
Calibration curves
To further investigate how error changes as the
uncertainty increases, we plotted calibration
curves of mean error per uncertainty bucket,
with the 95% confidence interval of error shown
for each bucket as error bars. We would like
uncertainty to serve as a proxy for error, so we
would hope to see the mean error for the sam-
ples in a bucket to increase as the UQ thresh-
old for that bucket increased. Results for neu-
ral network and random forest models built on
MOE feature vectors and neural network graph
convolution models are shown to demonstrate
the variation in performance.
For rat plasma clearance (in vivo), there is
an overall upward trend for all three calibra-
tion curves, but it is not completely monoton-
ically increasing for any of them. This is the
smallest dataset of our case study, so increas-
ing the bucket size may improve the choppiness
of these curves, but overall UQ does not look
like it would be a reliable proxy for error for
this dataset.
0.
99
1.
00
1.
00
1.
00
1.
01
1.
01
1.
02
1.
03
1.
05
1.
07
1.
11
1.
15
1.
21
1.
30
1.
39
1.
52
1.
67
1.
89
2.
30
6.
12
Uncertainty threshold
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Pr
ed
ict
io
n 
Er
ro
r
Figure 15: Mean error per uncertainty bucket
for rat plasma clearance (in vivo) neural net-
work model with MOE features
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Figure 16: Mean error per uncertainty bucket
for rat plasma clearance (in vivo) random forest
model with MOE features
Human microsomal clearance shows greater
variation in the calibration curves. For MOE
features with a neural network model, shows
an inverse pattern where the error actually
decreases as the uncertainty increases. For
MOE features with a random forest model,
there seems to be no correlation, except for
in the very highest bucket. The graph con-
volution model, conversely, shows an upward
trend, although it is not monotonically increas-
ing. These curves show that the featurizer and
model type have a strong effect on the relation-
ship between UQ and error.
For human plasma protein binding HSA,
which is the largest dataset with over 123,000
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Figure 17: Mean error per uncertainty bucket
for rat plasma clearance (in vivo) neural net-
work model with Graph Convolution features
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Figure 18: Mean error per uncertainty bucket
for human microsomal clearance neural network
model with MOE features
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Figure 19: Mean error per uncertainty bucket
for human microsomal clearance random forest
model with MOE features
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Figure 20: Mean error per uncertainty bucket
for human microsomal clearance neural network
model with Graph Convolution features
compounds, all calibration curves display the
desired behavior: error increases as uncertainty
increases and the 95 percent confidence inter-
vals are small.
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Figure 21: Mean error per uncertainty bucket
for human plasma protein binding HSA neural
network model with MOE features
Examining the relationship between UQ
and predicted value
Since the UQ values quantify the variation in
predictions, the relationship between UQ and
the predicted values were checked for evidence
of a correlation by examining plotted UQ versus
predicted values.
Rat plasma clearance (in vivo) shows a some-
what negative relationship, where the variation
in predictions decreases as the magnitude of the
predicted value increases. We found a similar
though much less pronounced trend when ex-
amining error versus predicted value, so it looks
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Figure 22: Mean error per uncertainty bucket
for human plasma protein binding HSA random
forest model with MOE features
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Figure 23: Mean error per uncertainty bucket
for human plasma protein binding HSA neu-
ral network model with Graph Convolution fea-
tures
like overall the model is predicting better for
compounds with higher clearance values.
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Figure 24: Uncertainty value versus Predicted
for rat plasma clearance (in vivo) neural net-
work model with MOE features
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Figure 25: Uncertainty value versus Predicted
for rat plasma clearance (in vivo) random forest
model with MOE features
For human microsomal clearance, MOE fea-
ture vectors yield models where the UQ is
strongly biased by the predicted value, espe-
cially for the neural network model, as seen in
Figure 27. Error versus predicted value does
not show this trend, so this is likely indicating
that UQ contains no real information value for
this model. This trend exists for the MOE ran-
dom forest model as well, although it levels off,
suggesting slightly less biased UQ values. The
graph convolution model displays a more bal-
anced relationship between UQ and predicted
value, which mirrors what we saw in the pre-
vious two sub-sections, that this model’s UQ is
more informative of error than the MOE mod-
els’ UQ. Human plasma protein binding HSA,
which showed the best calibration curves, also
shows the least correlation between UQ and
predicted value. UQ has a wide range of val-
ues for all predicted values.
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Figure 26: Uncertainty value versus Predicted
for rat plasma clearance (in vivo) neural net-
work model with Graph Convolution features
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Figure 27: Uncertainty value versus Predicted
for human microsomal clearance neural network
model with MOE features
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Figure 28: Uncertainty value versus Predicted
for human microsomal clearance random forest
model with MOE features
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Figure 29: Uncertainty value versus Predicted
for human microsomal clearance neural network
model with Graph Convolution features
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Figure 30: Uncertainty value versus Predicted
for human plasma protein binding HSA neural
network model with MOE features
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Figure 31: Uncertainty value versus Predicted
for human plasma protein binding HSA random
forest model with MOE features
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Figure 32: Uncertainty value versus Predicted
for human plasma protein binding HSA neu-
ral network model with Graph Convolution fea-
tures
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Correlation between UQ and error
While these plots provide useful methods for
visualizing the behavior of uncertainty quantifi-
cation, we wanted to identify a value that could
summarize if we could trust a given model’s
UQ results. Since we want the certainty of the
model to be reflected in accurate predictions,
we calculated the Spearman correlation coef-
ficient between between binned prediction er-
ror and UQ. Results are shown in Figure 33.
Correlations range from -0.088 to 0.33. While
these correlations are fairly low, all p-values are
< 0.05, and all but one are << 0.01, so there is
significance to the weak correlations identified.
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Figure 33: Spearman correlation coefficient be-
tween error and uncertainty values
Discussion
Key observations from the extensive series of
model evaluations are summarized here:
• Neural networks generally produced
more accurate models only on the larger
datasets.
• The proprietary MOE descriptors outper-
formed the open-source Mordred descrip-
tors for both random forest and neural
networks. Among neural network rep-
resentations, graph convolutions outper-
formed ECFP.
• A range of neural network architectures
performed best, depending on the dataset
size. Small networks appear to be promi-
nently featured in many datasets.
• Model performance generally improved
as dataset size increased, suggesting the
need for public dataset integration or
multi-task/ transfer learning approaches.
• Hyperparameter tuning generally im-
proved performance, in some cases dra-
matically.
• Uncertainty quantification showed a weak
correlation with error, and the efficacy
of using UQ to filter predictions varied
considerably between datasets and model
types.
The differences in prediction accuracy show
that the parameters needed for in silico drug
discovery present a diverse set of data-driven
modeling challenges. The extensive bench-
marking suggests that there is no clear one best
modeling approach for every predicted param-
eter. The differences in performance show the
importance of having a rigorous model building
pipeline that can be readily adapted and re-
applied to build parameter specific models as
new data becomes available.
Conclusions
In this paper, we present the ATOM Model-
ing PipeLine, or AMPL . This open-source soft-
ware suite allows the user to build global and
local models for a wide array of molecular prop-
erties that are needed for in silico drug dis-
covery. Results of extensive benchmarking on
a wide variety of pharmacokinetic and safety
datasets were also presented, with an explo-
ration of the effects of different featurization
and model types on model accuracy. While
the datasets used for developing and testing the
pipeline are not publicly available, the software
used to curate data and train, evaluate, and
share new models is available as open source
and benefits from having been tested on a wide
array of pharmaceutically-relevant parameters.
Additional public datasets are included with
the pipeline release to support applying repro-
ducible training and testing protocols that en-
able the broader modeling community to eval-
uate and improve modeling approaches over
time.
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Appendix
Benchmarking of AMPL on
public datasets
AMPL is open source and available for down-
load at
http://github.com/ATOMconsortium/AMPL.
To support reproducibility of this pipeline, we
provide model-building examples for three pub-
lic datasets in AMPL’s open source repository.
These datasets include:
• Delaney et al. solubility dataset24
• Wenzel et al. human liver microsome in-
trinsic clearance25
• Drug Target Commons KCNH2 (hERG)
inhibition assay26
Since the data from our main benchmarking ex-
periments are proprietary, we also benchmarked
AMPL on these publicly-available datasets.
Results are shown below.
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